Literature DB >> 21898483

Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.

Birgit Edlich1, Golo Ahlenstiel, Aintzane Zabaleta Azpiroz, Jonathan Stoltzfus, Mazen Noureddin, Elisavet Serti, Jordan J Feld, T Jake Liang, Yaron Rotman, Barbara Rehermann.   

Abstract

UNLABELLED: Natural killer (NK) cells exhibit a polarized phenotype with increased cytotoxicity and decreased interferon gamma (IFN-γ) production in chronic hepatitis C virus (HCV) infection. Here, we asked whether this is caused by type I interferon (IFN)-induced expression and phosphorylation levels of signal transducer and activator of transcription (STAT) molecules in NK cells and whether it affects the response and refractoriness of NK cells to IFN-α-based therapy of HCV. STAT1 levels in NK cells were significantly higher in patients with chronic HCV infection than in uninfected controls. STAT1 levels and induction of phosphorylated STAT1 (pSTAT1) increased further during IFN-α-based therapy with preferential STAT1 over STAT4 phosphorylation. Induction of pSTAT1 correlated with increased NK cytotoxicity (tumor necrosis factor-apoptosis-inducing ligand [TRAIL] expression and degranulation) and decreased IFN-γ production. NK cells from patients with a greater than 2 log(10) first-phase HCV RNA decline to IFN-α-based therapy (>99% IFN effectiveness) displayed strong pSTAT1 induction in vivo and were refractory to further stimulation in vitro. In contrast, NK cells from patients with a less than 2 log(10) first-phase HCV RNA decline exhibited lower pSTAT1 induction in vivo (P = 0.024), but retained greater IFN-α responsiveness in vitro (P = 0.024). NK cells of all patients became refractory to in vivo and in vitro stimulation by IFN-α during the second-phase virological response.
CONCLUSION: These data show that IFN-α-induced modulation of STAT1/4 phosphorylation underlies the polarization of NK cells toward increased cytotoxicity and decreased IFN-γ production in HCV infection, and that NK cell responsiveness and refractoriness correlate to the antiviral effectiveness of IFN-α-based therapy.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21898483      PMCID: PMC3353526          DOI: 10.1002/hep.24628

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

1.  Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection.

Authors:  Eui-Cheol Shin; Ulrike Seifert; Takanobu Kato; Charles M Rice; Stephen M Feinstone; Peter-M Kloetzel; Barbara Rehermann
Journal:  J Clin Invest       Date:  2006-10-12       Impact factor: 14.808

2.  Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox.

Authors:  K B Nguyen; L P Cousens; L A Doughty; G C Pien; J E Durbin; C A Biron
Journal:  Nat Immunol       Date:  2000-07       Impact factor: 25.606

3.  Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Authors:  Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

4.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Authors:  Jordan J Feld; Santosh Nanda; Ying Huang; Weiping Chen; Maggie Cam; Susan N Pusek; Lisa M Schweigler; Dickens Theodore; Steven L Zacks; T Jake Liang; Michael W Fried
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

Review 5.  Interferon-gamma: a historical perspective.

Authors:  Alfons Billiau; Patrick Matthys
Journal:  Cytokine Growth Factor Rev       Date:  2009-03-05       Impact factor: 7.638

6.  Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.

Authors:  Barbara Oliviero; Stefania Varchetta; Enrica Paudice; Giuseppe Michelone; Marco Zaramella; Domenico Mavilio; Francesca De Filippi; Savino Bruno; Mario U Mondelli
Journal:  Gastroenterology       Date:  2009-05-24       Impact factor: 22.682

7.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

8.  Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses.

Authors:  Golo Ahlenstiel; Maureen P Martin; Xiaojiang Gao; Mary Carrington; Barbara Rehermann
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells.

Authors:  Takuya Miyagi; M Pilar Gil; Xin Wang; Jennifer Louten; Wen-Ming Chu; Christine A Biron
Journal:  J Exp Med       Date:  2007-09-10       Impact factor: 14.307

View more
  52 in total

Review 1.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 2.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

3.  Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.

Authors:  Elisavet Serti; Xenia Chepa-Lotrea; Yun Ju Kim; Meghan Keane; Nancy Fryzek; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gastroenterology       Date:  2015-03-06       Impact factor: 22.682

4.  Natural killer and natural killer T cells in liver fibrosis.

Authors:  Bin Gao; Svetlana Radaeva
Journal:  Biochim Biophys Acta       Date:  2012-09-26

5.  Therapeutic depletion of natural killer cells controls persistent infection.

Authors:  Stephen N Waggoner; Keith A Daniels; Raymond M Welsh
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 6.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

7.  Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.

Authors:  Feng Qian; Christopher R Bolen; Chunxia Jing; Xiaomei Wang; Wei Zheng; Hongyu Zhao; Erol Fikrig; R Douglas Bruce; Steven H Kleinstein; Ruth R Montgomery
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 8.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

9.  Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Authors:  Xiaoli Hu; Yanfang Jiang; Xiurong Li; Yanhang Gao; Xiaoli Guo; Xiumei Chi; Hongqing Yan; Junyan Feng; Jin Zhong; Bing Sun; Xue Shao; Weihua Xiao; Yu Pan; Junqi Niu
Journal:  J Interferon Cytokine Res       Date:  2013-12-24       Impact factor: 2.607

10.  Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.

Authors:  Elisavet Serti; Heiyoung Park; Meghan Keane; Ashley C O'Keefe; Elenita Rivera; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gut       Date:  2016-01-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.